Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer

British Journal of Cancer

Volumn 99, Issue 3, 2008, Pages 491-501

  Landers, K A ^a,b   Samaratunga, H ^c   Teng, L ^a,b   Buck, M ^a,b   Burger, M J ^a,b   Scells, B ^a   Lavin, M F ^a,b   Gardiner, R A ^a,b,d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c SULLIVAN NICOLAIDES PATHOLOGY   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Claudin 4; Marker expression; Prostate cancer; RNA and protein

Indexed keywords

ANDROGEN; BIOLOGICAL MARKER; CALNEXIN; CLAUDIN 4; COMPLEMENTARY DNA; ENTEROTOXIN; RNA;

ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CELL JUNCTION; CLOSTRIDIUM PERFRINGENS; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA MICROARRAY; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; UPREGULATION; WESTERN BLOTTING;

BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; DNA PRIMERS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 48349141818     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604486     Document Type: Article

References (49)

1. Agarwal R, D'Souza T, Morin PJ (2005) Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res 65: 7378-7385
2. Boireau S, Buchert M, Samuel MS, Pannequin J, Ryan JL, Choquet A, Chapuis H, Rebillard X, Avancès C, Ernst M, Joubert D, Mottet N, Hollande F (2007) DNA-methylation-dependent alterations of claudin-4 expression in human bladder carcinoma. Carcinogenesis 28: 246-258
3. Bostwick DG, Liu L, Brawer MK, Qian J (2004) High-grade prostatic intraepithelial neoplasia. Rev Urol 6: 171-179
4. Bostwick DG, Norlen BJ, Denis L (2000) Prostatic intraepithelial neoplasia: the preinvasive stage of prostate cancer. Overview of the prostate committee report. Scand J Urol Nephrol Suppl 205: 1-2
5. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ (2000) Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum Pathol 31: 578-583
6. Burger MJ, Tebay MA, Keith PA, Samaratunga HM, Clements J, Lavin MF, Gardiner RA (2002) Expression analysis of delta-catenin and prostate-specific membrane antigen: their potential as diagnostic markers for prostate cancer. Int J Cancer 100: 228-237
7. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB (1999) Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 59: 3192-3198
8. Foster CS (2000) Pathology of benign prostatic hyperplasia. Prostate Suppl 9: 4-14
9. Freedland SJ, Presti Jr JC, Amling CL, Kane CJ, Aronson WJ, Dorey F, Terris MK, SEARCH Database Study Group (2003) Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology 61: 736-741
10. Fusi A, Procopio G, Della Torre S, Ricotta R, Bianchini G, Salvioni R, Ferrari L, Martinetti A, Salvelli G, Villa S, Bajetta E (2004) Treatment options in hormone-refractory metastatic prostate carcinoma. Tumori 90: 535-546
11. Hameed O, Humphrey PA (2005) p63/AMACR antibody cocktail restaining of prostate needle biopsy tissue after transfer to charged slides: a viable approach in the diagnosis of small atypical foci that are lost on block sectioning. Am J Clin Pathol 124: 708-715
12. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70
13. Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, Ries LA, Merrill RM, Kaplan RS (1999) Cancer surveillance series: interpreting trends in prostate cancer - part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 91: 1017-1024
14. Hessels D, Klein Gunnewiek JMT, van Oort I, Karthaus HFM, van Leenders GJL, van Balken B, Kiemeney LA, Witjes JA, Schalken JA (2003) DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44: 8-15
15. Hoedemaeker RF, Rietbergen JB, Kranse R, Schröder FH, van der Kwast TH (2000) Histopathological prostate cancer characteristics at radical prostatectomy after population based screening. J Urol 164: 411-415
16. Honda H, Pazin MJ, Ji H, Wernyj RP, Morin PJ (2006) Crucial roles of Sp1 and epigenetic modifications in the regulationof the CLDN4 promoter in ovarian cancer cells. J Biol Chem 281: 21433-21444
17. Jiang Z, Woda BA, Rock KL, Xu Y, Savas L, Khan A, Pihan G, Cai F, Babcook JS, Rathanaswami P, Reed SG, Xu J, Fanger GR (2001) P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol 25: 1397-1404
18. Katahira J, Inoue N, Horiguchi Y, Matsuda M, Sugimoto N (1997a) Molecular cloning and functional characterization of the receptor for Clostridium perfringens enterotoxin. J Cell Biol 136: 1239-1247
19. Katahira J, Sugiyama H, Inoue N, Horiguchi Y, Matsuda M, Sugimoto N (1997b) Clostridium perfringens enterotoxin utilizes two structurally related membrane proteins as functional receptors in vivo. J Biol Chem 272: 26652-26658
20. Kominsky SL, Vali M, Korz D, Gabig TG, Weitzman SA, Argani P, Sukumar S (2004) Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. Am J Pathol 164: 1627-1633
21. Landers KA, Burger MJ, Tebay MA, Purdie DM, Scells B, Samaratunga H, Lavin MF, Gardiner RA (2005) Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer 114: 950-956
22. Lee SK, Moon J, Park SW, Song SY, Chung JB, Kang JK (2005) Loss of the tight junction protein claudin 4 correlates with histological growth-pattern and differentiation in advanced gastric adenocarcinoma. Oncol Rep 13: 193-199
23. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander NH (1997) Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 57: 3629-3634
24. Long H, Crean CD, Lee WH, Cummings OW, Gabig TG (2001) Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. Cancer Res 61: 7878-7881
25. Martin TA, Jiang WG (2001) Tight junctions and their role in cancer metastasis. Histol Histopathol 16: 1183-1195
26. Massague J, Blain SW, Lo RS (2000) TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103: 295-309
27. Matsuda M, Sugimoto N (1979) Calcium-independent and dependent steps in action of Clostridium perfringens enterotoxin on HeLa and Vero cells. Biochem Biophys Res Commun 91: 629-636
28. Michl P, Barth C, Buchholz M, Lerch MM, Rolke M, Holzmann KH, Menke A, Fensterer H, Giehl K, Löhr M, Leder G, Iwamura T, Adler G, Gress TM (2003) Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer. Cancer Res 63: 6265-6271
29. Michl P, Buchholz M, Rolke M, Kunsch S, Löhr M, McClane B, Tsukita S, Leder G, Adler G, Gress TM (2001) Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology 121: 678-684
30. Montironi R, Mazzucchelli R, Scarpelli M (2002) Precancerous lesions and conditions of the prostate: from morphological and biological characterization to chemoprevention. Ann N Y Acad Sci 963: 169-184
31. Morita K, Furuse M, Fujimoto K, Tsukita S (1999) Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc Natl Acad Sci USA 96: 511-516
32. Morita K, Tsukita S, Miyachi Y (2004) Tight junction-associated proteins (occludin, ZO-1, claudin-1, claudin-4) in squamous cell carcinoma and Bowen's disease. Br J Dermatol 151: 328-334
33. Nichols LS, Ashfaq R, Iacobuzio-Donahue CA (2004) Claudin 4 protein expression in primary and metastatic pancreatic cancer: support for use as a therapeutic target. Am J Clin Pathol 121: 226-230
34. Ornstein DK, Tyson DR (2006) Proteomics for the identification of new prostate cancer biomarkers. Urol Oncol 24: 231-236
35. Rahner C, Mitic LL, Anderson JM (2001) Heterogeneity in expression and subcellular localization of claudins 2, 3, 4, and 5 in the rat liver, pancreas, and gut. Gastroenterology 120: 411-422
36. Rangel LB, Agarwal R, D'Souza T, Pizer ES, Alò PL, Lancaster WD, Gregoire L, Schwartz DR, Cho KR, Morin PJ (2003) Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 9: 2567-2575
37. Ross JS, Sheehan CE, Fisher HA, Kaufman Jr RP, Kaur P, Gray K, Webb I, Gray GS, Mosher R, Kallakury BV (2003) Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 9: 6357-6362
38. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh D, Chinnaiyan AM (2002) alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287: 1662-1670
39. Santin AD, Cane S, Bellone S, Palmieri M, Siegel ER, Thomas M, Roman JJ, Burnett A, Cannon MJ, Pecorelli S (2005) Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer Res 65: 4334-4342
40. Sato N, Fukushima N, Maitra A, Iacobuzio-Donahue CA, van Heek NT, Cameron JL, Yeo CJ, Hruban RH, Goggin M (2004) Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas. Am J Pathol 164: 903-914
41. Sheehan GM, Kallakury BV, Sheehan CE, Fisher HA, Kaufman Jr RP, Ross JS (2007) Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with prognostic variables in prostatic adenocarcinomas. Hum Pathol 38: 564-569
42. Smith DS, Catalona WJ (1994) The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 152: 1732-1736
43. Sommerfeld HJ, Meeker AK, Piatyszek MA, Bova GS, Shay JW, Coffey DS (1996) Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res 56: 218-222
44. Stark RL, Duncan CL (1971) Biological characteristics of Clostridium perfringens type A enterotoxin. Infect Immun 4: 89-96
45. Stephan C, Yousef GM, Scorilas A, Jung K, Jung M, Kristiansen G, Hauptmann S, Kishi T, Nakamura T, Loening SA, Diamandis EP (2004) Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. J Urol 171: 187-191
46. Tokes AM, Kulka J, Paku S, Szik A, Páska C, Novák PK, Szilák L, Kiss A, Bögi K, Schaff Z (2005) Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast Cancer Res 7: R296-R305
47. Weinstein RS, Merk FB, Alroy J (1976) The structure and function of intercellular junctions in cancer. Adv Cancer Res 23: 23-89
48. Wikstrom P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A (1998) Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 37: 19-29
49. Yang J, Mani SA, Weinberg RA (2006) Exploring a new twist on tumor metastasis. Cancer Res 66: 4549-4552s